AllDocs -> cancers

U . S . GOVERNMENT PRINTING OFFICE WASHINGTON : For sale by the Superintendent of Documents, U.S. Government Printing Office Internet: bookstore.gpo.gov Phone: toll free (866) 512–1800; DC area (202) 512–1800 Fax: (202) 512–2250 Mail: Stop SSOP, Washington, DC 20402–0001 76–311PS 2002 RAISING HEALTH AWARENESS THROUGH EXAM- INING BENIGN BRAIN TUMOR CANCER , ALPHA ONE, AND BREAST IMPLANT ISSUES HEARING BEFORE THE SUBCOMMITTEE ON HEALTH OF THE COMMITTEE ON ENERGY AND COMMERCE HOUSE OF REPRESENTATIVES ONE HUNDRED SEVENTH CONGRESS FIRST SESSION NOVEMBER 15, 2001 Serial No. 107–75 Printed for the use of the Committee on Energy and Commerce ( Available via the World Wide Web: http://www.access.gpo.gov/congress/house VerDate 11-MAY-2000 09:57 Jan 17, 2002 ...

80 18 Cancer of the brain Summary Relative survival after diagnosis of cancer of the brain is poor when compared with other cancers. During 1992–1997, relative survival one year after diagnosis was 42.2% for males and 41.1% for females. The five-year relative survival proportion after diagnosis of brain cancer was 23.8% for both males and females (Table 18.1). Ten-year relative survival was 21.4% for males and 21.9% for females in 1987–1991, the most recent period for which ten- year relative survival data are available (Figure 18.2; Tables 18.2 and 18.3). Relative survival after diagnosis remained fairly consistent between the periods 1982–1986 and 1992–1997, with no statistically significant trends for either males or females. Five-year relative survival was highest for males and females aged less than 40 years. Within this group, relative survival proportions were highest for males and ...

All-Ireland cancer statistics 1994-96 90 Brain 21. MALIGNANT CANCER OF THE BRAIN (summary) ICD-O.2 C71 ICD-10 C71 ICD-9 191 Figures presented are for primary, malignant tumours. Cancer of the meninges (ICD-10 C70) or of the central nervous system (C72) other than the brain itself are excluded, except where comparison is made with EU figures. Key facts • Average of 315 new cases per year, 1994-96: 148 in females, 200 in males. • Average of 297 deaths per year: 130 in females, 167 in males. • Age-standardised incidence and mortality rates about 50% higher in males than females. • 11th most common site for cancer incidence in males, 15th in females. • 8th most common cause of cancer deaths in females, 9th in males. • Median age at diagnosis 57 years for females and 55 years for males (lower than for cancers as a whole). ...

Stem cells track down brain cancer Scientists are excited about the idea that transplants of immature nerve cells may provide a treatment for strokes, Parkinson’s disease, and many other neurological conditions. Several studies presented in Miami Beach even hinted that these neural stem cells improve memory and learning skills when placed in the brains of aging rodents. Karen S. Aboody of Children’s Hospital in Boston and her colleagues now want to send such cells after brain tumors. Investigators have observed that neural stem cells, which are able to grow into any of the cell types in the brain , migrate to damaged areas. So, Aboody was curious whether these cells might home in on and infiltrate tumors. They do, even if injected on the opposite side of the brain from the cancer , according to her studies in rodents. The stem cells also seem to collect at the border where healthy tissue meets the tumor. Moreover, ...

Mathematical Modeling of Brain Cancer Page 1 Draft for Comment - Sept. 1999 Mathematical Modeling of Brain Cancer to Identify Promising Combination Treatments Background For aggressive brain cancers such as glioblastoma multiforme (gbm), much of the discussion on this web site and others are on clinical trials for new agents. This is largely because the existing arsenal of treatments is so weak. The clinical trials take drugs that seem promising and test them for safety and efficacy. The trials have prevented widespread use of agents that were dangerous, and have led to some improvements in brain tumor treatments. Life has been marginally extended. Newer treatments generally have fewer side effects than older ones for a similar level of effectiveness. However, taken in the broader context of the disease, the pace of progress through the conventional clinical trial approach ...

Table 1. Studies of Leukemia and Brain Cancer , and Occupational Exposure to Electromagnetic Fields included in Analysis. no. Reference Design Year Type exposure estimator All leukimia AML CLL Brain Tumors Relative risk Relative risk Relative risk Relative risk Occupational studies RR (95% C. I.) RR (95% C. I.) RR (95% C. I.) RR (95% C. I.) 1 Guralnick RC(M) 63 occ. electrical occupations 1.20 0.90 1.60 2 Peterson & Milham PM 80 occ. electrical occupations 0.90 0.60 1.30 3 Wiklund et al. RC(I) 81 occ. telephone operators 1.03 0.53 1.79 4 Milham(82,85b) PM 82 occ. 9 occupations 1.37 1.15 1.62 1.23 1.00 1.40 5 Preston-Martin et al. PI 82 occ. electricians 1.42 0.71 2.54 6 Wright et al. PI 82 occ. 11 occupations ...

Division of Environmental Epidemiology & Occupational Health 410 Capitol Avenue MS#11EOH PO Box 340308 Hartford, CT 06134-0308 • Many of the cases initially suggested by the union were ruled out because they were not malignant brain tumors. Some were brain tumors that were either benign (non-cancerous) or were a metastasis from an- other type of tumor. The brain is a common site to which a malignant tumor (a metastasis), which be- gins in another part in the body, can spread. Only malignant brain tumors were considered part of the investigation. Benign brain tumors have different risk factors. • There were four cases of primary, malignant (cancerous) brain tumors confirmed among white male employees at the P&W North Haven facility during the period 1991-1999. Three of these were the same type. The four individuals with primary brain tumors had worked ...

Page 2 Mortality trends in England; ICD9 (191), ICD10 (C71); File: Sepho 96-04 V2 Brain cancer in England 1996 to 2004. Mortality trends Authors: Michael Goldacre, Marie Duncan, Paula Cook-Mozaffari, Matthew Davidson, Henry McGuiness, Daniel Meddings Published by: Unit of Health-Care Epidemiology, Oxford University, and South-East England Public Health Observatory, 2006 This document provides a profile of trends in mortality for brain cancer in England. The period covered is January 1 1996 to December 31 2004. The data are analysed from mortality files supplied to the South East England Public Health Observatories (SEPHO) by the Office for National Statistics (ONS). Mortality rates were calculated for the condition certified as the underlying cause of death and for the disease certified as any mention on the death certificates. Age-specific ...

Vol. 7, No. 4 February 9, 2001 New USC neuro-oncologist seeks new ways to fight brain cancer The story seems apocryphal, she ad- mits. When Kathleen Squires was a little girl growing up overseas in places like Indonesia, she saw people around her with elephantiasis—enlarged, bulging legs due to lymphatic infection—and asked her dad why they suffered from the deforming condition. “They don’t have good medical care,” he explained. And so, though no one in her family worked in medicine, she decided she would be a doctor. Today, she is one of the newest medi- cal faculty members of the Keck School of Medicine of USC, focusing on infec- tious diseases. Specifically, Squires— visiting associate professor of medi- cine—treats patients with HIV and AIDS and performs research on drugs that might better help such patients. She also logs long ...

The GSM Association (GSMA) is the global trade association that exists to promote, protect and enhance the interests of GSM mobile operators throughout the world. www.gsmworld.com The MMF is an international association of wireless communications manufacturers established to support scientific research in relation to mobile telephony and health www.mmfai.info INTERPHONE: Mobile phone brain cancer study in the UK As part of the INTERPHONE project, UK medical researchers have published a large epidemiological study on the association between mobile phone use and the brain cancer , glioma * . The researchers were mostly medical statisticians and epidemiologists from various Centres and Institutes in England. The study was published on line in the British Medical Journal in January 2006. Study Design The study used a population based case-control design. The cases consisted ...

Research Provides Hope in the Fight Against Brain Cancer The National Brain Tumor Foundation announces 2005 Research Grant funding for promising research into brain tumor treatments and brain tumor causes. (PRWEB) August 10, 2005 -- The National Brain Tumor Foundation (NBTF), a non-profit organization dedicated to helping brain tumor patients and funding medical research, is proud to announce this year’s research awards. “For the past 25 years, NBTF has been funding research in the hope of improving treatment and eventually finding a cure,” says Rob Tufel, MSW, MPH, NBTF Executive Director. “ This is a time of great advancement in cancer research and NBTF funding can lead the way to a better understanding of brain cancer .” Each day more than 500 people are diagnosed with a brain tumor and there are 359,000 people living with a brain tumor in the United States. The National Brain Tumor ...

Researchers Search for Causes of Brain Cancer National Brain Tumor Foundation sponsors groundbreaking international research consortium in search for causes of brain tumors. San Francisco, CA (PRWEB) February 19, 2005 -- Cell phones, power lines, and diet have all been investigated as possible causes of brain tumors yet definitive answers continue to elude scientists. Each year, the public interest in wanting to know the causes of cancer grow yet research has been slow in finding answers. As a way of increasing our understanding of brain tumors and focusing more attention on causes, the National Brain Tumor Foundation is supporting a new international consortium of brain tumor researchers who hope to combine forces to better answers the question “What Causes Brain Tumors?” The purpose of this group, named the BTEC or the Brain Tumor Epidemiology Consortium, is to develop multi-center collaborations ...

1672 Main St. Ste. E #264 • Ramona, CA 92065 • Tel: 760.789.8928 • Fax: 760.789.8929 • Toll Free: 800.475.1955 • www.proteinbiotechnologies.com HUMAN BRAIN CANCER TISSUE ARRAY Catalog Number: TMA-139 Each dot represents a DISEASED tissue spot from one individual specimen that was selected and pathologically confirmed ( Brain glioma tissue array) Cases: 62 Cores: 63 Diameter: 1.5mm Thickness: 5 µm Standard IHC: GFAP confirmed Layout : 7 x 9 1 2 3 4 5 6 7 8 9 A 1 2 3 4 5 6 7 8 9 B 10 11 12 13 14 15 16 17 18 C 19 20 21 22 23 24 25 26 27 D 28 29 30 31 32 33 34 35 36 E ...

Abstract. Although conventional chemotherapies are used to treat patients with malignancies, damage to normal cells is problematic. Blood-forming bone marrow cells are the most adversely affected. It is therefore necessary to find alternative agents that can kill cancer cells but have minimal effects on normal cells. We investigated the brain cancer cell-killing activity of a homeopathic medicine, Ruta, isolated from a plant, Ruta graveolens . We treated human brain cancer and HL-60 leukemia cells, normal B-lymphoid cells, and murine melanoma cells in vitro with different concentrations of Ruta in combination with Ca 3 (PO 4 ) 2 . Fifteen patients diagnosed with intracranial tumors were treated with Ruta 6 and Ca 3 (PO 4 ) 2 . Of these 15 patients, 6 of the 7 glioma patients showed complete ...

www.datamonitor.com/healthcare Stakeholder Opinions: Primary Brain Cancer Temozolomide Turns Heads A Datamonitor Report Published: Jul-05 Product Code: DMHC2102 Use this Report to Understand the limitations of current therapy available to glioma patients Providing you with: • Overview of disease including epidemiology, biology of glioma and prognostic variables • Current treatment options and clinical controversies, including comments from opinion leaders • Key recommendations in the areas of greatest unmet need in glioblastoma patients • Profiles of agents in late stage development, including opinions from glioma specialists Page 2 Stakeholder Opinions: Primary Brain Cancer – Temozolomide Turns Heads DMHC2102 The incidence of glioblastoma is increasing. ...